Hematopoietic stem cell transplantation (HSCT) can be lifesaving for some of the deadliest hematologic diseases. However, immunosuppression, polypharmacy and risk of infectious complications associated with HSCT can increase morbidity and mortality for recipients. Incidence of acute kidney injury (AKI) after HSCT can be as high as 70%, and concomitant infection can be a therapeutic challenge for oncologists, nephrologists and infectious disease specialists. We illustrate this challenge in the case of a 31-year-old man with acute lymphoblastic leukemia who underwent a double cord HSCT complicated by GvHD, systemic cryptococcal and BK virus infections and AKI. Kidney biopsy showed round to cup-shaped organisms with occasional budding, consistent with Cryptococcus and thrombotic microangiopathy. We discuss our findings and a literature review of disseminated cryptococcal infection with renal involvement after HSCT.
INTRODUCTION
Acute kidney injury (AKI) is common in cancer patients and contributes to undue morbidity and mortality. Not only does AKI interrupt treatment regimens, but it also is an independent risk factor in hematopoietic stem cell transplantation (HSCT) for shortand long-term HSCT-related mortality, which increases if renal replacement therapy is required. 1 Causes of AKI include volume depletion, nephrotoxic medications, obstruction and aggressive diuresis. Other causes include hypercalcemia and intrinsic causes such as lymphomatous infiltration of the kidney, cast nephropathy, infection and tumor lysis syndrome. Most cases of AKI occur within 100 days of the transplantation and can be divided into early and late onset. Causes of early-onset AKI, occurring within 30 days of transplantation, include sepsis, nephrotoxin exposure, tumor lysis syndrome and veno-occlusive disease. Causes of late-onset AKI include thrombotic microangiopathy and calcineurin inhibitor toxicity. 1, 2 Infectious nephropathy associated with polyomavirus, CMV and adenovirus are notable causes of renal dysfunction and may present in the early and late engraftment periods. 3 Other lesswell reported infectious causes of renal dysfunction include urinary tract infections due to bacterial and fungal etiologies. We present a rare case of disseminated crytococcosis with renal involvement in a patient with ALL who underwent HSCT and developed AKI. The combination of infection and AKI presented substantial management challenges for the patient's care.
CASE REPORT
A 31-year-old man initially presented in early February 2013 with complaints of fatigue and was subsequently diagnosed with primary B-lineage acute lymphoblastic leukemia. The disease was refractory to three lines of chemotherapy, including blinatumomab (a bi-specific antibody construct directed towards CD3ζ and CD19). He did achieve CR with hyper CVAD (cyclophosphamide, vincristine, adriamycin, and dexamethasone) and inotuzumab (a monoclonal antibody directed toward CD22). He then underwent a double-cord HSCT in September 2013, conditioned with fludarabine and mephalan, which he tolerated well. Anti-thymocyte globulin, tacrolimus and mycophenolate mofetil was used for GvHD prophylaxis.
The year following HSCT, the patient was admitted to the hospital multiple times for several complications, including recurrent fevers despite various regimens of empiric, broadspectrum antimicrobials with antibacterial, antiviral and antifungal therapies. Outside of the hospital, he received standard prophylactic antimicrobials including oral cefpodoxime 200 mg twice daily, valacyclovir 500 mg daily and dapsone 100 mg daily. Two months post transplant, he developed portal hypertension and veno-occlusive disease, which precluded standard antifungal prophylaxis with voriconazole or posaconazole. Rather, he was treated with 50 mg of daily IV caspofungin due to less associated hepatotoxicity. Other complications within the first 60 days post transplant included anorexia, nausea and biopsy-confirmed grade 1 upper gastrointestinal GvHD for which he received budesonide, tacrolimus and mycophenolate mofetil.
During the first 100 days following his transplant, the patient went on to have infectious complications with Pseudomonas aeruginosa pneumonia and positive bronchial culture with Mycobacterium avium. Several months after these infections, he had pulmonary complications with dyspnea, recurrent pleural effusions and lung collapse. The diagnosis of disseminated cryptococcus was made based on antigen detection and positive cultures in the blood, pleural fluid and cerebrospinal fluid for Cryptococcus neoformans. He received liposomal amphotericin B (L-AMB) 5 mg/kg/day and flucytosine 25 mg/kg/day for 3 and 2 weeks, respectively, which resulted in clinical improvement and culture-negative cerebrospinal fluid. He was discharged with a regimen of 400 mg twice daily of oral fluconazole, to which the organism was susceptible (minimum inhibitory concentration = 1).
Approximately 2 weeks after discharge from the above hospitalization, the patient returned to the hospital with worsening pneumonia, pleural effusion and AKI with elevated creatinine level of 3.91 mg/dL (baseline of 0.9 mg/dL). The AKI was attributed to volume depletion in the setting of multiple antimicrobial nephrotoxins, including daily single-strength trimethoprim-sulfamethoxazole, valacyclovir 500 mg, spironolactone 50 mg and the previous L-AMB. Repeat thoracetentesis was performed and pleural cultures remained negative. However, cryptococcal antigen titers remained elevated, and the patient received another course of L-AMB and flucytosine for 3 and 2 weeks, respectively. At discharge, the patient was prescribed twice daily oral voriconazole 200 mg and continued on 4 mg/kg of IV L-AMB thrice weekly for an additional 6 weeks. At this point, his creatinine had improved to 1.96 mg/dL. Of note, voriconazole level obtained after discharge was elevated at 5.2 mcg/mL. Unfortunately, the patient was admitted a third time, 2 weeks later for worsening pleural effusions and renal dysfunction with creatinine of 4.1 mg/dL. He showed progressive renal failure with worsening creatinine, uremia, oliguria and volume overload not responsive to diuretic therapy. The patient was found to have BK viruria and viremia with 6 × 10 8 and 23 000 copies/mL detected, respectively. Hemodialysis was initiated, and further investigation with renal biopsy was performed. Renal biopsy showed diffuse mild-to-moderate mesangial expansion and focal segmental thickened capillary walls with wrinkled, sometimes doublecontoured basement membranes visualized with Jones silver stain. Two glomeruli had segmental thrombi with entrapped red blood cell fragments. These findings were consistent with active and evolving chronic thrombotic microangiopathy. In addition, periodic acid-Schiff and Gomori methenamine silver stains highlighted round-to-cup-shaped organisms with occasional budding scattered in the renal parenchyma and glomerular capillaries (Figure 1 ). These were histologically consistent with cryptococcal yeast. EM of a single available glomerulus showed diffuse mesangial matrix expansion and subendothelial rarefaction with relatively lucent fluff-like matrix. These changes are indicative of endothelial injury and consistent with thrombotic microangiopathy. Also present in a single segmental glomerular capillary was a leukocyte containing intracellular organisms with electron-dense cell walls consistent with Cryptococcus (Figure 2 ).
During this last hospitalization, the patient continued on voriconazole twice daily for treatment of disseminated cryptococcosis with renal involvement. L-AMB was precluded due to his renal dysfunction. Multiple blood cultures, pleural fluid culture, urine and ascitic fluid cultures remained negative. His a b c d Figure 1 . Glomeruli with segmental thrombi with entrapped intact and fragmented RBC (a) and segmental double contours (b; Jones silver stain). Round, budding organisms within the glomerular capillaries (c; periodic acid-Schiff ) and renal parenchyma (d; Gomori silver stain) were also observed.
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DISCUSSION
Cryptococcal infections are often associated with conditions of cellular immune dysfunction or deficiency such as HIV. Other diseases, such as lymphoproliferative disorders, diabetes and cirrhosis, have been associated with cryptococcal infections. 4, 5 Prolonged exposure to immunomodulatory agents such as corticosteroids, chemotherapies and some monoclonal antibodies may also increase the risk of infection owing to induced T-cell dysfunction. 6, 7 The global burden of cryptococcal infection in the HIV population alone is estimated to be about 1 million cases and nearly 625 000 deaths per year due to central nervous system disease. 8 However, most epidemiologic data on cryptococcal infections come from the HIV population, and these data may underrepresent the total burden of disease in non-HIV-infected groups such as those with malignancies.
Patients who have undergone organ transplantation, either solid organ transplantation or HSCT, are well known to be at risk of cryptococcal disease. Cryptococcal disease is the third most common invasive fungal infection among solid organ transplantation recipients. 9 However, due to the effective antifungal prophylaxis, it is significantly rarer among HSCT recipients, representing o 1% of invasive fungal infections in this population. 10 The risk for invasive fungal infections overall remains highest among HSCT recipients with an unrelated donor or mismatched related donor. 10 Myeloablative regimens are most commonly associated with the development of invasive fungal disease. 10 The increased use of nonmyeloablative approaches with agents such as fludarabine has improved treatment-related morbidity; however, these approaches also are associated with risk of invasive fungal disease owing to cell-mediated immune dysfunction.
11 Agents used to prevent GvHD such as alemtuzumab, an anti-CD52 monoclonal antibody, have also been associated with the development of cryptococcal and other fungal infections. 12 Furthermore, the timing of cryptococcal infection after HSCT is not well defined. One case series reported that time from HSCT to diagnosis of cryptococcal infection ranged from 12 days to 4 months. Sites of infection in these HSCT patients included meningitis, fungemia and pneumonia. 13 Cryptococcal renal disease has not been well documented, and only few studies have examined the incidence. A single-center study in 1972 evaluated 32 patients with a serologic or pathologic diagnosis of C. neoformans infection before or after death. Eight of these patients had disseminated disease and five of the eight with disseminated disease had renal involvement.
14 Interestingly, the most commonly associated disease was lymphoma, which occurred in about one-third of the patients. Another single-center study in India analyzed 90 patients with fungal infections between 1981 and 2001. Twenty of 39 patients with cryptococcosis had renal involvement that were found only at autopsy. No patient had isolated renal involvement, and no case of AKI was attributable to cryptococcal infection. 15 Treatment of disseminated cryptococcosis with renal dysfunction is a challenge for clinicians. Infectious disease guidelines for treating disseminated disease involving the central nervous system, as in our patient involves the use of nephrotoxic agents such as L-AMB for at least 2 weeks. 15 Our patient received two separate courses of liposomal L-AMB and flucytosine, then fluconazole and voriconazole. Given the patient's progressive hemodialysis-dependent renal failure, safely and adequately treating the cryptococcosis was a dilemma.
Disseminated cryptococcal infection with renal involvement is certainly possible, as documented in our case report; however, the incidence and clinical impact upon renal function is unknown. Information in the literature documenting the frequency of renal involvement in cryptococcal infection is limited to autopsy reports and few case reports. 16, 17 The renal failure in our patient was likely multifactorial and due to the acute and evolving thrombotic microangiopathy secondary to the presence of GvHD, tacrolimus exposure and possibly the presence of cryptoccocal infection as reported in a few case reports leading to disseminated intravascular coagulation. [18] [19] [20] In addition, there is increasing evidence that endothelial injury in the kidney may be secondary to circulating inflammatory cytokines related to GvHD elsewhere in the body. 21 One may argue that in the setting of negative urine cultures for cryptoccocal infection that the presence of crytoccocci in the renal parenchyma were not actively contributing to the renal injury. Although quantitative PCR on serum was positive, immunohistochemistry for SV40 large T antigen showed no evidence of polyomavirus-infected renal tubular epithelial cells and therefore BK infection did not have a role in the renal dysfunction in this case. At this time, more information is needed to determine the impact of cryptococcal infections upon renal function.
In conclusion, HSCT recipients are at high risk of development of AKI due to many etiologies, including infectious-and non-infectious-related insults. Disseminated cryptococcosis is an a b uncommon finding in HSCT recipients, but may involve multiple body compartments organs including the renal parenchyma and glomeruli. The clinical significance of renal cryptococcosis remains undefined, but may be yet another insult to renal function and treatment dilemma in populations vulnerable to AKI.
